Clinical economic analysis as a constituent part of the metabolic syndrome pharmacotherapy optimization

Authors

  • M. M. Zayats
  • A. B. Zimenkovskyy

DOI:

https://doi.org/10.14739/2310-1210.2013.4.16827

Keywords:

metabolic syndrome, clinical and economic analysis, ABC/VEN analysis, frequency analysis, pharmacotherapy, drugs

Abstract


The object of the research: complex retrospective clinical economic analysis of the pharmacotherapy of patients with metabolic syndrome at the stage of inpatient care.

Materials of and methods: hospital medical records (lists of drug prescriptions in the amount of 60) concerning patients who received treatment in the in-patient therapeutic department of one of Lviv healthcare institutions in 2011. The methods used for the attaining the aim were as follows: bibliographic, analytic, comparative, pharmacoeconomic analysis.

Results: the results of the held analysis testified that treatment of patients took in general 14,53±3,66 “hospital” days. Summarily for 60 patients were ordered 420 drug prescriptions during the dwell time. Study was  carried out according to the ATC Classification System and gave opportunity to define the main groups of drugs, notably those related to the code C - Cardiovascular system (43,75%) and code A - Alimentary tract and metabolism (38,75%). The results of the next stage of the clinical economic study (ABC/VEN analysis) verified 10491,5 hryvnas (UH) to be spent for carrying out the pharmacotherapy. The group A according to the ABC analysis consisted of 13 drugs for which 79,78% of funds (8368,77 UH) was spent up. Only 2 of the foregoing drugs refer to the basic medication had direct indications for MS. The rest of drugs were prescribed for the correction of the cardiac and endocrine complications and treatment of the concomitant diseases. Carrying out the parallel ABC/VEN analysis testified that group A is compounded of 1 vital, 7 essential and 5 non-essential drugs.

Conclusions: complex retrospective clinical economic analysis can serve the base for the creation of the local drug formularies in cardiologic, therapeutic, endocrine clinics etc. on purpose to rationalize budgetary funds for the MS pharmacotherapy.

References

Lakka H.M. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men / Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpussalo E, Tuomilehto J, Salonen JT. // JAMA. – 2002. – Vol. 288. – P. 2709–2716.OS

Mancia G. Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study / Mancia G., Bombelli M., Corrao G. et al. // Hypertension. – 2007. – Vol. 49. – P. 40.

Базовий термінологічний глосарій за програмою з клінічної фармації: науково-довідкове видання / [А.Б. Зіменковський, В.М.Пономаренко, О.Р. Піняжко, Т.Г. Калинюк]. – Львів; Київ: Ліга-Прес, 2004. – 446 с.

Державний формуляр лікарських засобів / МОЗ України, Державний фармакологічний центр; за ред. В.Т. Чумака. – Вип. ІV. – К., 2010. – Елекронний ресурс – Режим доступу http:// www.pharma-center.kiev.ua/view/formylar

Наказ МОЗ України від 27.02.2006 р. №86 «Перелік лікарських засобів вітчизняного та іноземного виробництва, які можуть закуповувати заклади й установи охорони здоров’я, що повністю або частково фінансуються з державного та місцевих бюджетів» із змінами, затвердженими наказом МОЗ України від 16.03.2007 р. №123.

Національний перелік основних лікарських засобів (Постанова КМУ №333 від 25.03.2009 р.).

Воробьев П.А. Клинико-экономический анализ в медицинской организации. Практическое руководство для лиц, принимающих решения / Воробьев П.А. //Национальная фармакотерапия.– 2009. – №1. – Електронний ресурс. – Режим доступу: http://rpt.health-ua.com/article/1202.html

How to Cite

1.
Zayats MM, Zimenkovskyy AB. Clinical economic analysis as a constituent part of the metabolic syndrome pharmacotherapy optimization. Zaporozhye Medical Journal [Internet]. 2013Sep.3 [cited 2024Dec.24];15(4). Available from: http://zmj.zsmu.edu.ua/article/view/16827

Issue

No. 4 (2013): Zaporozhye medical journal

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)